General Biologicals Corporation (GBC)

General Biologicals Corporation (GBC), established in 1984 and headquartered in Hsinchu Science Park, Taiwan, is a leading manufacturer of in-vitro diagnostic (IVD) devices. The company specializes in developing high-quality diagnostic tools that aid clinical decisions in areas such as hepatitis, tumor markers, retroviruses, fertility, thyroid, and steroids.​

Core Competencies

Precision Diagnostics (IVD): GBC offers a range of immunoassay platforms, including ELISA and CLIA, for detecting various biomarkers. Their real-time PCR assays provide precise detection of viral infections like HBV, HCV, and HIV.​

CellBio™ Liquid Biopsy Platform: This proprietary platform enables the detection of circulating tumor cells (CTCs) from blood samples, facilitating early cancer detection and monitoring.​

P113 Antimicrobial Peptide: GBC has developed P113, an antimicrobial peptide derived from human saliva, which has demonstrated efficacy against various bacteria and fungi. It is being explored for applications in oral care and as a potential therapeutic agent.